Vir Biotechnology (VIR) Payables (2018 - 2026)
Vir Biotechnology recorded quarterly Payables of $5.4 million in Q1 2026, down 44.46% quarter-over-quarter from $9.8 million in Q4 2025, and up 46.17% year-over-year from $3.7 million in Q1 2025.
Vir Biotechnology's Payables history runs 9 years deep, the most recent figure standing at $5.4 million for Q1 2026.
- In Q1 2026, Payables rose 46.17% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 46.17% YoY), while the FY2025 annual figure was $9.8 million, up 92.93% from the prior year.
- Payables came in at $5.4 million for Q1 2026 at Vir Biotechnology, down from $9.8 million in the prior quarter.
- In the past five years, Payables ranged from a high of $12.4 million in Q2 2023 to a low of $2.7 million in Q3 2022.
- A 5-year average of $7.5 million and a median of $6.8 million in 2025 frame the typical range for Payables.
- Across the five-year window, Payables jumped 196.0% in 2022 and plunged 64.5% in 2024, its largest moves.
- Vir Biotechnology's Payables stood at $6.4 million in 2022, then dropped by 1.37% to $6.3 million in 2023, then decreased by 19.78% to $5.1 million in 2024, then jumped by 92.93% to $9.8 million in 2025, then plunged by 44.46% to $5.4 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $5.4 million, $9.8 million, and $6.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 300,549.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.69 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | 5.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.45 Mn |
| Dec 31, 2025 | 9.80 Mn |
| Sep 30, 2025 | 6.85 Mn |
| Jun 30, 2025 | 12.23 Mn |
| Mar 31, 2025 | 3.73 Mn |
| Dec 31, 2024 | 5.08 Mn |
| Sep 30, 2024 | 7.31 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 7.11 Mn |
| Dec 31, 2023 | 6.33 Mn |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 12.36 Mn |
| Mar 31, 2023 | 12.15 Mn |
| Dec 31, 2022 | 6.42 Mn |
| Sep 30, 2022 | 2.72 Mn |
| Jun 30, 2022 | 10.62 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2021 | 6.52 Mn |
| Sep 30, 2021 | 4.23 Mn |
| Jun 30, 2021 | 11.03 Mn |
| Mar 31, 2021 | 3.70 Mn |
| Dec 31, 2020 | 5.08 Mn |
| Sep 30, 2020 | 6.80 Mn |
| Jun 30, 2020 | 4.38 Mn |
| Mar 31, 2020 | 18.77 Mn |
| Dec 31, 2019 | 5.88 Mn |
| Sep 30, 2019 | 5.82 Mn |
| Dec 31, 2018 | 6.47 Mn |